Comparative Pharmacology
Head-to-head clinical analysis: CARDENE IN 5 0 DEXTROSE IN PLASTIC CONTAINER versus COVERA HS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE IN 5 0 DEXTROSE IN PLASTIC CONTAINER versus COVERA HS.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs COVERA-HS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.
Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.
Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.
180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.
None Documented
None Documented
2 to 4 hours in healthy subjects; increased in hepatic impairment (up to 7 hours) and in elderly. No significant change in renal impairment.
Terminal elimination half-life is 6–17 hours for immediate-release; for Covera-HS (controlled-onset extended-release), the half-life is 10–20 hours, allowing once-daily bedtime dosing to achieve peak effect in the morning.
Primarily hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 60-70% of total elimination, with renal excretion of metabolites approximately 30-40%.
Primarily hepatic metabolism (oxidation and glucuronidation) with renal excretion of inactive metabolites; approximately 80% of metabolites are excreted renally and 15% fecally.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker